Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 8,000 shares, a decrease of 51.2% from the October 15th total of 16,400 shares. Based on an average daily trading volume, of 28,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the company’s shares are short sold.

Insider Buying and Selling at Assembly Biosciences

In related news, major shareholder Alexander Schornstein bought 10,000 shares of the business’s stock in a transaction on Tuesday, October 8th. The shares were purchased at an average price of $14.58 per share, with a total value of $145,800.00. Following the completion of the purchase, the insider now owns 703,113 shares of the company’s stock, valued at $10,251,387.54. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

A number of hedge funds have recently modified their holdings of the business. Armistice Capital LLC acquired a new stake in shares of Assembly Biosciences during the second quarter worth about $6,421,000. Renaissance Technologies LLC lifted its stake in Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after acquiring an additional 15,451 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in Assembly Biosciences by 131.0% during the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 7,690 shares during the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Analyst Ratings Changes

ASMB has been the topic of a number of research analyst reports. Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $2.00 to $35.00 in a research report on Friday, September 20th. HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research report on Tuesday, September 24th.

Assembly Biosciences Stock Up 1.0 %

NASDAQ ASMB opened at $16.57 on Wednesday. The stock’s 50-day moving average is $16.72 and its 200-day moving average is $15.25. Assembly Biosciences has a one year low of $7.69 and a one year high of $19.93.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.